Entity family

Browse drugs

Named medicines, compounds, vaccines, and pharmacological agents. Examples include metformin, semaglutide, antibiotics.

10,506articles mentioning drugs

58,393drug mentions

9,496distinct drugs extracted

0%of mentions human-reviewed

Filter articles

JournalContent resourceEvidence policyAutomated confidence floorArticles per pageReset filters

“Reviewed + threshold” includes every confirmed correction plus unreviewed proposals at or above the selected model score.

All extracted drugs

Showing 7,621–7,680 of 9,496, ordered by supporting articles. Choose a drug to see its evidence.

angiotensin II1 angiotensin II inhibitors1 angiotensin II receptor blocker1 angiotensin converting enzyme (ACE) inhibitor1 angiotensin converting enzyme inhibitors-angiotensin II receptor blockers1 anifrolumabAbstract1 anlotinib-induced1 antacid1 anthelmintic medication1 anthelmintics1 anti PD-11 anti-4-1BB1 anti-B7-H3 antibody‒drug conjugate1 anti-BAFF1 anti-CD38 mAb1 anti-CD38 monoclonal antibodies1 anti-CD401 anti-CD40 agonist antibody1 anti-CD47 monoclonal antibody1 anti-CGRP monoclonal antibodies1 anti-CTLA-4 antibody1 anti-CTLA-4 mAb1 anti-CTLA4 antibody1 anti-HER2 antibody-drug conjugates1 anti-Ly6G1 anti-MDA5 antibody1 anti-Mullerian Hormone1 anti-Müllerian hormone1 anti-OA pharmacological agents1 anti-OX401 anti-PD-(L)1-based1 anti-PD-1 ICB1 anti-PD-L1 avelumab1 anti-Parkinson’s drugs1 anti-Sjögren’s syndrome antigen A1 anti-TIM-31 anti-Th/To-positive1 anti-VEGF agents1 anti-VEGFR21 anti-anginal medication1 anti-cancer compounds1 anti-cytotoxic T lymphocyte-associated antigen-4 immune checkpoint inhibitors1 anti-diabetic agents1 anti-fibrotic medications1 anti-histamines1 anti-hypertensive drugs1 anti-infectious agents1 anti-inflammatory drugs1 anti-inflammatory reliever1 anti-interferon1 anti-oestrogen medications1 anti-pan γδ x CD1231 anti-pan γδ x CD123 bispecific antibody1 anti-programmed cell death protein 11 anti-programmed cell death protein 1 (PD1)1 anti-programmed cell death protein-1/programmed death-ligand 11 anti-programmed death (ligand) 11 anti-programmed death-ligand 1 (PD-(L)1)1 anti-programmed death-ligand 1 (PD-L1)1 anti-programmed death-ligand 1 antibodies1

View all 9,496 drugs on one page

Articles mentioning drugs

10,506 articles · page 86 of 876

5 Immunomodulation of tumor microenvironment in triple negative breast cancer by reversing hypoxia with NanO2, a novel oxygen delivery agent

jitc · abstract · 2025-11-04 · 12 matching annotations

97.3%

NanO 2 NanO2 Paclitaxel Glioblastoma Multiforme TNBC Triple-negative breast cancer DOD Grant BALB/c mice

…oxygenation strategies remain limited for clinical translation. NanO 2 (NuvOx Pharma), a novel perfluorocarbon-based oxygen therapeuti…

632 In situ APMV-4 vaccination achieves systemic tumor clearance and long-term antitumor immunity, priming response to sub-therapeutic dosing of aCTLA-4 in colorectal carcinoma

jitc · abstract · 2025-11-04 · 12 matching annotations

97.5%

APMV-4 Ipilimumab aCTLA-4 CTLA-4 Icahn School of Medicine at Mount Sinai CRC

… tumors and tumor draining lymph nodes to unveil the effects of APMV-4 ISV on host immune responses. Ex vivo splenocyte stimulation wa…

635 The impact of bispecific antibody CD22xCD28 on anti-tumor efficacy of odronextamab and T cell activation and function in B cell tumor models

jitc · abstract · 2025-11-04 · 12 matching annotations

98.8%

Odronextamab REGN5837 odronextamab-mediated non-Hodgkin lymphoma DLBCL follicular lymphoma diffuse large B cell lymphoma

…ent strategies are required to achieve durable tumor rejection. Odronextamab, a CD20xCD3 bispecific antibody, has been approved in the EU fo…

657 Targeting glycolysis by pramlintide suppresses tumor growth in preclinical models of ewing sarcoma and offers opportunities for combination with immunotherapy

jitc · abstract · 2025-11-04 · 12 matching annotations

98.6%

pramlintide Ewing sarcoma type II Diabetes EWS prostate carcinoma

…ing tumor acidity and reshaping the metabolic microenvironment, pramlintide may enhance immune cell trafficking and function, supporting it…

680 Assessing outcomes in melanoma patients with brain metastases: a retrospective study of immunotherapy, radiation, and surgical treatment sequencing

jitc · abstract · 2025-11-04 · 12 matching annotations

91.6%

ipilimumab nivolumab ICI immune checkpoint inhibitors melanoma Brown University Health

…lick AC, Jiang J, Avila A, … Margolin K. Combined nivolumab and ipilimumab in melanoma metastatic to the brain. The New England Journal of…

681 TNG260, a novel small-molecule CoREST inhibitor, sensitizes STK11-mutant tumors to anti-PD-1 therapy

jitc · abstract · 2025-11-04 · 12 matching annotations

98.3%

TNG260 pembrolizumab TNG260-induced NSCLC Non-small cell lung cancer NCT05887492 immune checkpoint-based therapies

…tial treatment strategy for patients with STK11-mutated tumors. TNG260 in combination with pembrolizumab is currently being evaluated …

690 Boosting treatment outcomes for high-grade serous ovarian cancer via the integration of antibody-drug conjugates and immune system stimulants

jitc · abstract · 2025-11-04 · 12 matching annotations

94.5%

Trastuzumab emtansine trastuzumab CBD-IL-7 T-DM1PMPC CBD-IL-12 T-DM1 Imperial College London High-grade serous ovarian carcinoma (HGSOC)University of Alabama at Birmingham epithelial ovarian cancer

…ulatory cytokines, intensifying the anti-tumor response.Methods Trastuzumab emtansine (T-DM1, KADCYLA) served as the lead ADC. To increase the drug p…

708 Overcoming resistance to chemo-immunotherapy in non-small cell lung cancer by targeting adenosine metabolism and enhancing CD8+ T cell activation

jitc · abstract · 2025-11-04 · 12 matching annotations

98.3%

cisplatin carboplatin cisplatin-induced cisplatin-treated PEG-ADA NSCLC non-small cell lung cancer

…ti-PD-1 or anti-PD-L1 antibodies) plus concurrent chemotherapy (cisplatin or carboplatin) is now part of the standard of care for non-sma…

760 Tumor oxidative metabolism exhibits atypical dependence on two mitochondrial complex I subunits that are dispensable for T cell function

jitc · abstract · 2025-11-04 · 12 matching annotations

93.6%

OxPhos NDUFS4 NDUFA7 gastric cancer MC38 murine colorectal cancer

…the metabolic and functional suppression observed with existing OxPhos inhibitors. In vivo, NDUFA7 knockdown MC38 tumors show signific…

851 Conditional immune activation with daiad-2/15: a targeted, hyperpotent IL-2/IL-15 agonist with an engineered logic gate

jitc · abstract · 2025-11-04 · 12 matching annotations

93.9%

Daiad-2/15 Daiad TM-2/15 Neo-2/15 IL-2 IL-15 vascular leak syndrome cytokine release syndrome

…nt on the same cell.Conclusions Together, our data suggest that Daiad-2/15 could potentiate the systemic delivery of a highly potent immun…

942 An mRNA-encoded adjuvant delivered via lipid nanoparticles induces interferon signaling and converts immune cold tumors to hot in patient-derived organotypic tumor spheroids

jitc · abstract · 2025-11-04 · 12 matching annotations

89.5%

cGASΔN-LNPs cGASΔN-LNP αPD-L1 monoclonal antibody GFP-LNPs GFP-LNP endometrial cancer WCG Institutional Review Board

…nto microfluidic devices, and treated with GFP-LNPs (10 µg/ml), cGASΔN-LNPs (1 and 10 µg/ml), or αPD-L1 monoclonal antibody (300 µg/ml). GF…

957 Modulation of the tumor immune microenvironment by low dose antibody-based radiopharmaceutical therapy (RPT) and direct visualization of RPT analog microdistribution by imaging mass cytometry

jitc · abstract · 2025-11-04 · 12 matching annotations

89.4%

177Lu-A2DM 177Lu-RPT 177Lu 169Tm-A2DM 225Ac-A2DM 225Ac-RPT A2DM pancreatic cancers City of Hope Institutional Animal Care and Use Committee RPT

…t 48 hr. For low-dose RPT, mice were administered 225Ac-A2DM or 177Lu-A2DM, and tumors collected at days 4, 7 and/or 14. Tissues were form…